Ignite Creation Date:
2024-05-06 @ 7:42 PM
Last Modification Date:
2024-10-26 @ 3:12 PM
Study NCT ID:
NCT06103383
Status:
RECRUITING
Last Update Posted:
2024-03-12
First Post:
2023-10-23
Brief Title:
Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women
Sponsor:
Instituto Valenciano de Infertilidad IVI VALENCIA
Organization:
Instituto Valenciano de Infertilidad IVI VALENCIA
Study Overview
Official Title:
Second Phase of the Pilot Study for Obtaining Mature Oocytes by in Vitro Maturation in Oocyte-donor Women
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MIVODON-II
Brief Summary:
In vitro maturation IVM is a technique for obtaining potentially fertilizable oocytes from immature oocytes An oocyte must be mature both nuclearly and cytoplasmically in order to be competent in the reproductive process Nuclear maturation involves an oocyte in metaphase II stage and is easily evaluated for its morphology However cytoplasmic maturation can only be evaluated by in vitro fertilization of that oocyte A mature nuclear and cytoplasmic oocyte is the one capable of producing a viable embryo This study aims to optimize the in vitro maturation IVM technique to achieve nuclear mature oocytes ie to mature the oocytes up to the metaphase II stage In addition an artificial oocyte activation AOA will be carried out to check the cytoplasmic maturation of the oocytes avoiding the generation of potentially viable embryos
This study corresponds to a second phase of the pilot study for the development of this technique in our IVF laboratory We will use all we have learned in the first phase as well as the experience acquired to advance in the optimization of this protocol
The correct functioning of this IVM technique would mean a reduction in the costs of ovarian stimulation treatments as lower doses and shorter stimulation times are required which implies lower risks for women derived from the medication and less stress for them
This study corresponds to a second phase of the pilot study for the development of this technique in our IVF laboratory We will use all we have learned in the first phase as well as the experience acquired to advance in the optimization of this protocol
The correct functioning of this IVM technique would mean a reduction in the costs of ovarian stimulation treatments as lower doses and shorter stimulation times are required which implies lower risks for women derived from the medication and less stress for them
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None